Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if 5-aza-2 deoxycytidine (decitabine)
given in combination with Mylotarg (gemtuzumab ozogamicin) can help to control Acute myeloid
leukemia (AML), high-risk myelodysplastic syndromes (MDS) or Myelofibrosis (MF). The safety
of this drug combination will also be studied.